Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology

Executive Summary

RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.

You may also be interested in...



RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand

French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC125204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel